In order to prevent spam,
this email address cannot be copied.
Researcher Profile - Julian Thorpe Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Community: Researcher Profiles
Researcher Profile

RESEARCHER INFORMATION
First Name:Julian
Last Name:Thorpe
Title:Dr.
Advanced Degrees:D.Phil.
Affiliation:University of Sussex
Department:EM Division, The Sussex Centre for Advanced Microscopy
Street Address 1:School of Life Sciences
Street Address 2:Falmer
City:Brighton
State/Province:East Sussex
Zip/Postal Code:BN1 9QG
Country/Territory:United Kingdom
Phone:+44 (0)1273 877585
Fax:+44 (0)1273 678433
Disclosure:
(view policy) 
Member reports no financial or other potential conflicts of interest. [Last Modified: 4 April 2012]
View all comments by Julian Thorpe
Clinical Interests:
Tauopathies, Aging Process, Alzheimer Disease
Research Focus:
Microscopy, Animal Models, Oxidative Stress, Apoptosis/Cell cycle, A-beta PP/A-beta, Neuropathology, Tau/Cytoskeleton
Work Sector(s):
University
Web Sites:
Personal: http://www.lifesci.sussex.ac.uk/home/Julian_Thorpe/ad_cover.htm
Professional: http://www.sussex.ac.uk/
Lab: http://www.sussex.ac.uk/lifesci/thorpelab/
Researcher Bio
I am a biological electron microscopist by training. An interest in one particular protein, Pin1, has led me into the field of AD and the tauopathies. The development in this laboratory of a novel TEM labelling method utilising Pin1 (Thorpe et al., 1999) and the revelation of the involvement of Pin1 in AD (Lu et al., 1999) came fortuitously together at almost the same time. It would appear that Pin1 brings together many facets of AD, having an involvement in tangle formation , along with probable involvements in APP proteolysis (and thence plaque formation), the spurious up-regulation of cell cycle events , apoptosis and dysregulation of the Notch and Wnt pathways (via its interaction with beta-catenin).
Top Papers
Soura V, Stewart Parker M, Williams TL, Ratnayaka A, Atherton J, Gorringe K, Tuffin J, Darwent E, RambaranR, Klein W, Lacor P, Staras K, Thorpe J, Serpell L (2012) Visualisation of colocalisation in Ab42-administered neuroblastoma cells reveals lysosome damage and autophagosome accumulation related to cell death. Biochemical Journal 441:579-590

Page T, Gitcho MA, Mosaheb S, Carter D,Chakraverty S, Perry RH, Bigio EH, Gearing M, Ferrer I, Goate AM, Cairns NJ, Thorpe JR (2011) FUS immunogold labelling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy. Journal of Molecular Neuroscience 45: 409-421 DOI: 10.1007/s12031-011-9549-8

Acevedo-Arozena A, Kalmar B, Essa S, Ricketts T, Joyce P, Kent R, Rowe C, Parker A, Gray A, Hafezparast M, Thorpe JR, Greensmith L, Fisher EMC (2011) A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Disease Models & Mechanisms 4: 686-700

Paine S, Bedford L, Thorpe JR, Mayer RJ, Bajaj N, Sheppard PW, Lowe J, Layfield R (2009) Immunoreactivity to Lys63-linked polyubiquitin is a feature of neurodegeneration. Neuroscience Letters 460: 205-208

Thorpe JR, Tang HHL, Atherton JM, Cairns NJ (2008) Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. Journal of Neural Transmission 115: 1661-1671

Hashemzadeh-Bonehi L, Phillips RG, Cairns NJ, Mosaheb S, Thorpe JR (2006) Pin1 protein associates with neuronal lipofuscin: potential consequences in age-related neurodegeneration. Experimental Neurology 199: 328-338

MOSAHEB S, THORPE JR, HASHEMZADEH-BONEHI L, BIGIO EH, GEARING M, CAIRNS NJ (2005) Neuronal intranuclear inclusions are ultrastructurally and immunologically distinct from cytoplasmic inclusions of neuronal intermediate filament inclusion disease (NIFID). Acta Neuropathologica 110: 360-368

THORPE JR, MOSAHEB S, HASHEMZADEH-BONEHI L, CAIRNS NJ, KAY KE, MORLEY SJ, RULTEN S (2004) Shortfalls in the Peptidyl-Prolyl Cis-Trans Isomerase Protein Pin1 in Neurons are Associated With Frontotemporal Dementias. Neurobiology of Disease 17: 237-249

CAIRNS NJ, GROSSMAN M, ARNOLD SE, BURN DJ, JAROS E, PERRY RH, DUYCKAERTS C, STANKOFF B, PILLON B, SKULLERUD K, CRUZ-SANCHEZ FF, BIGIO EH, MACKENZIE IRA, GEARING M, JUNCOS JL, GLASS JD, YOKOO H, NAKAZATO Y, MOSAHEB S, THORPE JR, URYU K, LEE V.M.-Y, TROJANOWSKI, JQ (2004) Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease (NIFID). Neurology 63: 1376-1384

THORPE, J.R., MORLEY, S.J. and RULTEN, S.L. (2001) Utilising the Peptidyl- Prolyl Cis-Trans Isomerase Pin1 as a Probe of its Phosphorylated Target Proteins: Examples of Binding to Nuclear Proteins in a Human Kidney Cell Line and to Tau in Alzheimer’s Diseased Brain. J. Histochem. Cytochem. 49: 97-108


What is the greatest void to date in our knowledge of Alzheimer's Disease?
An overall comprehension of the process and progress of the disease that draws together its many facets and identifies the most likely points of effective therapeutic intervention.
What are the top three papers (not yours) you have read recently?
George R. Jackson, Martina Wiedau-Pazos, Tzu-Kang Sang, Naveed Wagle, Carlos A. Brown, Sasan Massachi and Daniel H. Geschwind (2002) Human Wild-Type Tau Interacts with wingless Pathway Components and Produces Neurofibrillary Pathology in Drosophila Neuron 34: 509-519
Mudher A, Lovestone S (2002)Alzheimer’s disease – do tauists and baptists finally shake hands? Trends in Neurosciences 25: 22-26
Lee, VMY, Goedert, M and Trojanowski, JQ (2001)
Neurodegenerative tauopathies. ANNUAL REVIEW OF NEUROSCIENCE 24: 1121-1159
If resources were not limited, what research projects would you pursue?
I would continue my research on Pin1 protein as it appears to bring together many facets of AD, having an involvement in tangle formation, along with probable involvements in APP proteolysis (and thence plaque formation), the spurious up-regulation of cell cycle events, apoptosis and dysregulation of the Notch and Wnt pathways (via its interaction with beta-catenin).
What is your leading hypothesis?
That nuclear Pin1 depletion - in the presence of associated upregulation of cell cycle events - in AD leads to nuclear instability and apoptosis, and that this depletion might well be a unifying, contributory factor towards neuronal cell death in AD and potentially all the tauopathies.
What piece of missing evidence would help prove it?
Correlating the timing of nuclear depletion of Pin1 and increased amounts, and the identification, of phosphorylated nuclear Pin1 targets with the appearance of apoptotic markers would be a starting point.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad